| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PMIC.201100092 |
| P8608 | Fatcat ID | release_r3wohgomrfc2zie2u5xv3lpzly |
| P698 | PubMed publication ID | 21761561 |
| P5875 | ResearchGate publication ID | 230255473 |
| P50 | author | Elena Di Gennaro | Q57061563 |
| Alessandra Leone | Q57629449 | ||
| Francesca Bruzzese | Q63737239 | ||
| Assunta Gagliardi | Q84205148 | ||
| Laura Bianchi | Q38640243 | ||
| Luca Bini | Q38640254 | ||
| Alfredo Budillon | Q40122753 | ||
| P2093 | author name string | Biagio Pucci | |
| Alessandro Armini | |||
| Monia Rocco | |||
| Michele Puglia | |||
| Anna Gimigliano | |||
| P2860 | cites work | Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition | Q53657859 |
| Ebp1 isoforms distinctively regulate cell survival and differentiation | Q24296796 | ||
| Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation | Q24298757 | ||
| HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation | Q24310722 | ||
| Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor | Q24318682 | ||
| Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress | Q24336513 | ||
| Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells | Q24634268 | ||
| EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance | Q24646417 | ||
| Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases | Q24680884 | ||
| TCTP protects from apoptotic cell death by antagonizing bax function | Q27649850 | ||
| The translationally controlled tumour protein (TCTP) | Q28235318 | ||
| Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells | Q28250203 | ||
| The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species | Q28349324 | ||
| Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set | Q28389579 | ||
| Retracted: Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies | Q28473693 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor | Q30636308 | ||
| Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. | Q33187257 | ||
| Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines | Q33390295 | ||
| Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells | Q33490663 | ||
| Characterization of side population cells from laryngeal cancer cell lines | Q33525639 | ||
| Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat | Q33588300 | ||
| Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. | Q33636849 | ||
| Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors | Q33697130 | ||
| Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway | Q33744417 | ||
| Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription | Q33893105 | ||
| Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. | Q33926784 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences | Q34336945 | ||
| Metabolism and proliferation share common regulatory pathways in cancer cells | Q34419460 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. | Q36109012 | ||
| Discovery and development of SAHA as an anticancer agent | Q36745383 | ||
| Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. | Q37066999 | ||
| Development of vorinostat: current applications and future perspectives for cancer therapy | Q37381104 | ||
| p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. | Q37419204 | ||
| HDACi--targets beyond chromatin. | Q37430947 | ||
| Neuroendocrine differentiation of LNCaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathway | Q37504211 | ||
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. | Q39527047 | ||
| Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors | Q39628667 | ||
| Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. | Q39706465 | ||
| Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib | Q39707468 | ||
| Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. | Q39718130 | ||
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis | Q39779497 | ||
| An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen | Q39854940 | ||
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed | Q39875582 | ||
| Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines | Q39894634 | ||
| A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells | Q39978575 | ||
| Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. | Q40000114 | ||
| Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells | Q40095635 | ||
| Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition | Q40120317 | ||
| Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma | Q40125585 | ||
| Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells | Q40125627 | ||
| Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. | Q40327522 | ||
| MBP-1 physically associates with histone deacetylase for transcriptional repression | Q40942403 | ||
| New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors | Q41127315 | ||
| Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei | Q41862279 | ||
| Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells | Q44323774 | ||
| Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death | Q44863828 | ||
| Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy | Q45245923 | ||
| PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). | Q47367777 | ||
| 2D-DIGE: comparative proteomics of cellular signalling pathways | Q47982902 | ||
| Epithelial-mesenchymal transition and the invasive potential of tumors. | Q51959766 | ||
| P433 | issue | 18 | |
| P304 | page(s) | 3725-3742 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Proteomics | Q15614164 |
| P1476 | title | Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells | |
| P478 | volume | 11 |
| Q41616038 | Cytoskeleton and nuclear lamina affection in recessive osteogenesis imperfecta: A functional proteomics perspective. |
| Q58752227 | Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: A proteomic approach |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q38645501 | Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. |
| Q37577433 | Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. |
| Q36203560 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial |
| Q35497211 | Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype |
| Q39514941 | Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. |
| Q36459159 | Proteomic profile identifies dysregulated pathways in Cornelia de Lange syndrome cells with distinct mutations in SMC1A and SMC3 genes. |
| Q46038047 | Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. |
Search more.